César Alejandro
Soutullo Esperón
Ikertzailea 2019-(e)ra arte
![Foto de Tobias](/img/nophoto.png)
Tobias
Banaschewski
Tobias Banaschewski-rekin lankidetzan egindako argitalpenak (10)
2020
-
ADHD management during the COVID-19 pandemic: guidance from the European ADHD Guidelines Group
The Lancet Child and Adolescent Health
2018
-
Growth and Puberty in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
CNS Drugs, Vol. 32, Núm. 5, pp. 455-467
-
Practitioner review: Current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder
Journal of Child Psychology and Psychiatry and Allied Disciplines, Vol. 59, Núm. 9, pp. 932-947
2017
-
Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe
CNS Drugs, Vol. 31, Núm. 7, pp. 625-638
-
Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder
European Child and Adolescent Psychiatry, Vol. 26, Núm. 11, pp. 1283-1307
2016
-
Neurofeedback for Attention-Deficit/Hyperactivity Disorder: Meta-Analysis of Clinical and Neuropsychological Outcomes From Randomized Controlled Trials
Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 55, Núm. 6, pp. 444-455
2014
-
Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the treatment of attention-deficit/ hyperactivity disorder in a randomized, Controlled trial
Neuropsychiatric Disease and Treatment, Vol. 10, pp. 2039-2047
2013
-
A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents
CNS Drugs, Vol. 27, Núm. 9, pp. 743-751
-
European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder
European Neuropsychopharmacology, Vol. 23, Núm. 10, pp. 1208-1218
-
Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder
CNS Drugs, Vol. 27, Núm. 10, pp. 829-840